Caleb Appleton

Bison Ventures is a venture capital firm that invests in early-stage frontier technology companies focused on creating healthier people and a healthier planet. Bison partners with entrepreneurs that are using breakthrough science and innovative technology to create new categories or re-define existing ones.

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions

The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University was created jointly by the Emory University School of Medicine and the Georgia Tech College of Engineering. As such, we offer the best of both internationally renowned institutions. We are united by our dedication to improving the health and well-being of all by fostering the next generation of leaders in biomedical engineering worldwide. We are highly collaborative, interdisciplinary innovators in basic and translational research and education. We are far-sighted educators, dedicated to creating biomedical engineers equipped for success today and in the future, across all realms of the burgeoning field.

Bison Ventures is a venture capital firm that invests in early-stage frontier technology companies focused on creating healthier people and a healthier planet. Bison partners with entrepreneurs that are using breakthrough science and innovative technology to create new categories or re-define existing ones.

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions

The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University was created jointly by the Emory University School of Medicine and the Georgia Tech College of Engineering. As such, we offer the best of both internationally renowned institutions. We are united by our dedication to improving the health and well-being of all by fostering the next generation of leaders in biomedical engineering worldwide. We are highly collaborative, interdisciplinary innovators in basic and translational research and education. We are far-sighted educators, dedicated to creating biomedical engineers equipped for success today and in the future, across all realms of the burgeoning field.

Innovation Endeavors is an early-stage venture capital firm that invests in cutting-edge technologies to drive generational change in order to solve problems that matter. The firm’s central investment thesis, the Super Evolution, combines data, computational capacity, and advanced engineering to transform a range of industries including engineering health, climate, computing infrastructure, intelligent software, the physical economy, and more. Its investments include Afresh, AlphaSense, Atom Computing, Color, Gatik, Eikon Therapeutics, Fabric, Homelight, Kong, Formlabs, Panther, Planet, Replica, SoFi, Uber, Upstart, Vicarious Surgical, and more.

Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future. Across 65 cities in 40 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a platinum rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 1% of all companies. Since our founding in 1973, we have measured our success by the success of our clients.